25.05.2012                      04.Siwan. 5772                    Tag 48 des Omer

Wirtschaft:

Teva revises 2012 outlook lower on poor European conditions

Under the new forecast, the world's biggest maker of generic drugs expects net sales to reach between $20 billion and $21 billion this year.

Teva Pharmaceutical Industries on Thursday revised its 2012 revenue and profit forecast downward, citing weakness in its Europe markets.
Under the new forecast, the world's biggest maker of generic drugs expects net sales to reach between $20 billion and $21 billion this year – as much as $2 billion less than its previous forecast made last December….